维生素 D 代谢物和类似物在慢性肾脏病治疗中的应用。
The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease.
机构信息
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55901, USA.
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55901, USA; Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55901, USA.
出版信息
Endocrinol Metab Clin North Am. 2017 Dec;46(4):983-1007. doi: 10.1016/j.ecl.2017.07.008. Epub 2017 Sep 29.
Abstract
Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are associated with abnormalities in bone and mineral metabolism, known as CKD-bone mineral disorder. CKD and ESRD cause skeletal abnormalities characterized by hyperparathyroidism, mixed uremic osteodystrophy, osteomalacia, adynamic bone disease, and frequently enhanced vascular and ectopic calcification. Hyperparathyroidism and mixed uremic osteodystrophy are the most common manifestations due to phosphate retention, reduced concentrations of 1,25-dihydroxyvitamin D, intestinal calcium absorption, and negative calcium balance. Treatment with 1-hydroxylated vitamin D analogues is useful.
摘要
慢性肾脏病（CKD）和终末期肾病（ESRD）与骨和矿物质代谢异常有关，被称为 CKD-矿物质骨异常。CKD 和 ESRD 引起的骨骼异常的特征为甲状旁腺功能亢进、混合性尿毒症性骨营养不良、骨软化症、动力缺失性骨病，并且常常伴有血管和异位钙化增强。甲状旁腺功能亢进和混合性尿毒症性骨营养不良是最常见的表现，这是由于磷酸盐潴留、1,25-二羟维生素 D 浓度降低、肠道钙吸收和负钙平衡所致。用 1 羟化维生素 D 类似物治疗是有用的。
相似文献
1
The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease.维生素 D 代谢物和类似物在慢性肾脏病治疗中的应用。
Endocrinol Metab Clin North Am. 2017 Dec;46(4):983-1007. doi: 10.1016/j.ecl.2017.07.008. Epub 2017 Sep 29.
2
Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.慢性肾脏病继发性甲状旁腺功能亢进的治疗结果及直接治疗成本
J Manag Care Pharm. 2007 Jun;13(5):397-411. doi: 10.18553/jmcp.2007.13.5.397.
3
Prevention of metabolic bone disease in the pre-end-stage renal disease setting.终末期肾病前期代谢性骨病的预防
J Am Soc Nephrol. 1998 Dec;9(12 Suppl):S71-7.
4
Are new vitamin D analogues in renal bone disease superior to calcitriol?治疗肾性骨病的新型维生素D类似物是否优于骨化三醇？
Pediatr Nephrol. 2005 Mar;20(3):393-8. doi: 10.1007/s00467-004-1788-2. Epub 2005 Feb 3.
5
Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.慢性肾脏病中的肾性骨病与死亡率：重新审视维生素D、拟钙剂、碱性磷酸酶及矿物质的作用
Kidney Int Suppl. 2010 Aug(117):S10-21. doi: 10.1038/ki.2010.189.
6
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
7
[Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].[尿毒症性骨营养不良的机制及尿毒症患者甲状旁腺功能亢进的预防]
G Ital Nefrol. 2003 May-Jun;20 Suppl 22:S12-6.
8
Paricalcitol as compared with calcitriol in patients undergoing hemodialysis.接受血液透析患者中帕立骨化醇与骨化三醇的比较。
N Engl J Med. 2003 Jul 31;349(5):496-9. doi: 10.1056/NEJMe038104.
9
Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.维生素D、维生素D受体及其激活在慢性肾脏病患者中的重要性。
Nefrologia. 2015;35(1):28-41. doi: 10.3265/Nefrologia.pre2014.Sep.11796.
10
Vitamin D analogues for the management of secondary hyperparathyroidism.用于治疗继发性甲状旁腺功能亢进的维生素D类似物。
Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S34-40. doi: 10.1053/ajkd.2001.28109.
引用本文的文献
1
Management of rickets: the new horizons for the pediatrician.佝偻病的管理：儿科医生的新视野
J Health Popul Nutr. 2025 Aug 26;44(1):310. doi: 10.1186/s41043-025-00885-4.
2
Vitamin D Supplementation: Practical Advice in Different Clinical Settings.维生素D补充：不同临床环境下的实用建议
Nutrients. 2025 Feb 24;17(5):783. doi: 10.3390/nu17050783.
3
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD).肥胖与慢性肾脏病（CKD）的心脏代谢合并症及并发症
J Clin Transl Endocrinol. 2024 Apr 2;36:100341. doi: 10.1016/j.jcte.2024.100341. eCollection 2024 Jun.
4
Association of serum vitamin D concentration with the final course of hospitalization in patients with COVID-19.血清维生素 D 浓度与 COVID-19 患者住院最终结局的相关性。
Front Immunol. 2023 Sep 1;14:1231813. doi: 10.3389/fimmu.2023.1231813. eCollection 2023.
5
Effects of Different Routes and Forms of Vitamin D Administration on Mesenteric Lymph Node CD4+ T Cell Polarization and Intestinal Injury in Obese Mice Complicated with Polymicrobial Sepsis.不同途径和形式的维生素 D 给药对肥胖合并脓毒症小鼠肠系膜淋巴结 CD4+T 细胞极化和肠道损伤的影响。
Nutrients. 2022 Aug 29;14(17):3557. doi: 10.3390/nu14173557.
6
Effect of Vitamin D on Graft-versus-Host Disease.维生素D对移植物抗宿主病的影响。
Biomedicines. 2022 Apr 24;10(5):987. doi: 10.3390/biomedicines10050987.
7
Skeletal and extraskeletal disorders of biomineralization.生物矿化的骨骼和骨骼外紊乱。
Nat Rev Endocrinol. 2022 Aug;18(8):473-489. doi: 10.1038/s41574-022-00682-7. Epub 2022 May 16.
8
Changes in Metabolic Parameters in Patients with Diabetic Kidney Disease Depending on the Status of D3.根据 D3 状态变化，糖尿病肾病患者代谢参数的变化。
Rev Recent Clin Trials. 2022;17(4):280-290. doi: 10.2174/1574887117666220321152855.
9
The Emerging Role of Nutraceuticals in Cardiovascular Calcification: Evidence from Preclinical and Clinical Studies.营养保健品在心血管钙化中的新兴作用：来自临床前和临床研究的证据。
Nutrients. 2021 Jul 28;13(8):2603. doi: 10.3390/nu13082603.
10
Vitamin D and Temporomandibular Disorders: What Do We Know So Far?维生素 D 与颞下颌关节紊乱病：目前我们了解多少？
Nutrients. 2021 Apr 14;13(4):1286. doi: 10.3390/nu13041286.
本文引用的文献
1
The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder.完整肾单位假说：概念及其对 CKD 相关矿物质和骨代谢紊乱中磷酸盐管理的影响。
Kidney Int. 2011 Apr;79121:S3-8. doi: 10.1038/ki.2011.23.
2
Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects.维生素D：代谢、作用的分子机制及多效性作用
Physiol Rev. 2016 Jan;96(1):365-408. doi: 10.1152/physrev.00014.2015.
3
1α,25-Dihydroxyvitamin D3 Regulates Mitochondrial Oxygen Consumption and Dynamics in Human Skeletal Muscle Cells.1α,25-二羟基维生素D3调节人骨骼肌细胞中的线粒体氧消耗和动力学。
J Biol Chem. 2016 Jan 15;291(3):1514-28. doi: 10.1074/jbc.M115.684399. Epub 2015 Nov 24.
4
Deletion of the intestinal plasma membrane calcium pump, isoform 1, Atp2b1, in mice is associated with decreased bone mineral density and impaired responsiveness to 1, 25-dihydroxyvitamin D3.在小鼠中，肠道质膜钙泵亚型1（Atp2b1）的缺失与骨矿物质密度降低以及对1,25 - 二羟基维生素D3的反应性受损有关。
Biochem Biophys Res Commun. 2015 Nov 6;467(1):152-6. doi: 10.1016/j.bbrc.2015.09.087. Epub 2015 Sep 21.
5
Nutritional vitamin D supplementation in dialysis: a randomized trial.透析患者补充营养性维生素D：一项随机试验。
Clin J Am Soc Nephrol. 2015 Apr 7;10(4):611-9. doi: 10.2215/CJN.06910714. Epub 2015 Mar 13.
6
Reduced renal calcium excretion in the absence of sclerostin expression: evidence for a novel calcium-regulating bone kidney axis.在缺乏硬化蛋白表达的情况下肾钙排泄减少：一种新型钙调节骨-肾轴的证据
J Am Soc Nephrol. 2014 Oct;25(10):2159-68. doi: 10.1681/ASN.2014020166. Epub 2014 May 29.
7
Detection of 1α,25-dihydroxyvitamin D-regulated miRNAs in zebrafish by whole transcriptome sequencing.通过全转录组测序检测斑马鱼中1α,25-二羟基维生素D调节的微小RNA
Zebrafish. 2014 Jun;11(3):207-18. doi: 10.1089/zeb.2013.0899. Epub 2014 Mar 20.
8
Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD).维生素D与慢性肾脏病-矿物质和骨异常（CKD-MBD）。
Bonekey Rep. 2014 Feb 5;3:498. doi: 10.1038/bonekey.2013.232. eCollection 2014.
9
The SLC34 family of sodium-dependent phosphate transporters.SLC34 家族的钠离子依赖型磷酸盐转运蛋白。
Pflugers Arch. 2014 Jan;466(1):139-53. doi: 10.1007/s00424-013-1418-6. Epub 2013 Dec 19.
10
Variability in free 25(OH) vitamin D levels in clinical populations.临床人群中游离 25(OH) 维生素 D 水平的变异性。
J Steroid Biochem Mol Biol. 2014 Oct;144 Pt A:156-8. doi: 10.1016/j.jsbmb.2013.11.006. Epub 2013 Nov 15.
Zotero 插件